Quotient announces extension of RapidFACT™ into non-oral routes of delivery
Nottingham, U.K, (19th March 2013) –Quotient Clinical, part of Quotient Bioresearch (“Quotient”) today announced that three new pharma and biotech clients have selected its RapidFACT™ service to support the development of optimal drug products for pulmonary, transdermal, and ocular administration. This marks a key extension in the application of RapidFACT™ across a wide range of dosage forms and delivery routes.
RapidFACT™ (Rapid Formulation development And Clinical Testing) is underpinned by a Translational Pharmaceutics platform that integrates formulation development, “real-time” GMP product manufacturing, and clinical testing. Compared to conventional development processes, RapidFACT™ shortens development timelines, lowers costs, and also reduces the consumption of drug substance by up to 90%.
Mark Egerton, Managing Director of Quotient Clinical, said:
“We are delighted that RapidFACT™ has been selected to support the development of these exciting new products. To date, RapidFACT™ has been deployed on over 30 programs that have focused on oral delivery or intranasal delivery. These new programs further demonstrate the broad utility of RapidFACT™ and our belief that it can be used to support the development of molecules for any route of delivery.”